SCHEMBL2494868

SCHEMBL2494868

Nc1nc2ccccc2n1-c1ccc(O)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR2 Q92731 5/20 0.62
ESR1 P03372 4/20 0.62
GRIA1 P42261 1/20 0.56
CACNG8 Q8WXS5 1/20 0.56
CACNG2 Q9Y698 1/20 0.56
NOS2 P35228 1/20 0.50
ADORA2A P29274 2/20 0.48
ADORA3 P0DMS8 1/20 0.48
FGFR1 P11362 1/20 0.47
HTT P42858 2/20 0.46
MAPK1 P28482 1/20 0.46
KDM4E B2RXH2 1/20 0.46
CYP1A2 P05177 1/20 0.45
CYP2D6 P10635 1/20 0.45
CXCR4 P61073 1/20 0.45
MEN1 O00255 1/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
KMT2A Q03164 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7168183 0.86 NOS2 (0.53) ESR2ESR1NOS2ADORA2AADORA3
SCHEMBL2309144 0.85 MAPK1 (0.61) ESR2ESR1NOS2HTTMAPK1
Hydrochloric Acid SCHEMBL7167676 0.84 NOS2 (0.52) ESR2ESR1NOS2ADORA2AADORA3
SCHEMBL5945572 0.83 ESR1 (0.54) ESR2ESR1GRIA1CACNG8CACNG2
SCHEMBL7294918 0.83 NOS2 (0.50) ESR2ESR1NOS2HTTMAPK1
SCHEMBL15214855 0.83 L3MBTL1 (0.56) ESR2ESR1NOS2ADORA2AADORA3
SCHEMBL9995179 0.83 NPC1 (0.52) ESR2ESR1NOS2ADORA2AHTT
SCHEMBL17602705 0.82 NOS2 (0.46) ESR2ESR1GRIA1CACNG8CACNG2
SCHEMBL16826857 0.79 NOD1 (0.57) NOS2ADORA2AHTTMAPK1CYP1A2
SCHEMBL10176264 0.79 ADORA2A (0.49) ESR2ESR1NOS2ADORA2AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2373163-B1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE GENENTECH INC (US) 2015-06-10 EP disclosed
CN-102316733-B Heterocyclic compounds and methods of use GENENTECH INC 2014-01-01 CN disclosed
US-8232273-B2 Heterocyclic compounds and methods of use GENENTECH, INC. (US) 2012-07-31 US disclosed
CN-102316733-A HETEROCYCLIC COMPOUNDS AND METHODS OF USE INST MEDICAL W & E HALL 2012-01-11 CN disclosed
EP-2373163-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE Genentech, Inc. (US) 2011-10-12 EP disclosed
US-20100210622-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE ABBVIE INC. 2010-08-19 US disclosed
WO-2010080503-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE GENENTECH, INC. (US) 2010-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100210622-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE BCL2A1, BAX, BCL2 ESR2 260/4885ESR1 415/4885GRIA1 3113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.